Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyó JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF; Rapamune Maintenance Regimen Study Group. Russ G, et al. Among authors: schena fp. Transplantation. 2005 Nov 15;80(9):1204-11. doi: 10.1097/01.tp.0000178393.78084.9b. Transplantation. 2005. PMID: 16314787 Clinical Trial.
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group. Schena FP, et al. Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41. Transplantation. 2009. PMID: 19155978 Clinical Trial.
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES; Sirolimus CONVERT Trial Study Group. Alberú J, et al. Among authors: schena fp. Transplantation. 2011 Aug 15;92(3):303-10. doi: 10.1097/TP.0b013e3182247ae2. Transplantation. 2011. PMID: 21792049 Clinical Trial.
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.
Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF; Rapamune Maintenance Regimen Trial. Kreis H, et al. Among authors: schena fp. J Am Soc Nephrol. 2004 Mar;15(3):809-17. doi: 10.1097/01.asn.0000113248.59077.76. J Am Soc Nephrol. 2004. PMID: 14978184 Clinical Trial.
A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, Rigotti P, Cossu M, Altieri P, Salvadori M, Federico S, Stefoni S, Cambi V, Albertazzi A, Buoncristiani U, Berloco P, Segoloni G, Boschiero L, Sparacino V, Donati D, Turello E, Dal Canton A, Ponticelli C. Montagnino G, et al. Among authors: schena fp. Transplant Proc. 2005 Mar;37(2):788-90. doi: 10.1016/j.transproceed.2004.11.033. Transplant Proc. 2005. PMID: 15848532 Clinical Trial.
464 results